Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT02335437 Completed - Clinical trials for Fatigue Syndrome, Chronic

Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents

CEBA
Start date: March 2015
Phase: N/A
Study type: Observational

Chronic fatigue syndrome (CFS) is characterized by unexplained, disabling and long lasting fatigue, as well as pain, impaired memory, sleep difficulties and other symptoms. Epstein-Barr virus (EBV) infection might precipitate CFS. In this study, 200 adolescents undergoing acute EBV infection will be followed prospectively, and also compared with a group of healthy controls. The aim is twofold: - To identify factors that predispose to chronic fatigue among adolescents with acute EBV infection - To compare pathophysiological features of patients with acute EBV infection with a group of healthy controls. Possible risk factors for chronic fatigue 6 months after EBV-infection includes: - Severity of the initial infection - Immune responses characteristics - Characteristics of the neuroendocrine stress response - Cognitive functioning - Emotional disturbances - Genetics/ epigenetics of candidate genes - Certain personality traits - Critical life events

NCT ID: NCT02328963 Completed - Clinical trials for Cytomegalovirus Infection

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

EVERCMV
Start date: May 2, 2014
Phase: Phase 4
Study type: Interventional

Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals. The goal of this study is to demonstrate that an immunosuppressive regimen associating everolimus and reduced dose of cyclosporine A can prevent acute rejection episodes as efficiently as standard regimen but also efficiently reduce the incidence of CMV infection at 6 months post-transplantation.

NCT ID: NCT02327520 Completed - Clinical trials for Clostridium Difficile Infection

Clostridium Difficile Infection: the First Report in Southeast Asia by 2010 Nationwide Study

Start date: January 2010
Phase: N/A
Study type: Observational

The authors retrieved in-patient medical data, including the expense, from the 2010 Thailand Nationwide Hospital Admission Database, which is part of the National Health Security Office (NHSO). The diagnosis of digestive diseases with any form of colitis listed in the causes, either as principal diagnosis or co-morbidity, coding by the ICD-10 was recorded. The inclusion criteria were: 1) diagnosis of enterocolitis due to Clostridium difficile (ICD10-A07); and 2) age of more than 18 years. If the data was incomplete, the case was excluded. The baseline characteristics, including age, sex, co-morbidity disease and history of endoscopy or surgery, were recorded. The burden of CDI was evaluated by length of hospital stay (LOS), mortality rate, and hospital charge.

NCT ID: NCT02326636 Completed - Clinical trials for Clostridium Difficile Infection

Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection

FMT
Start date: April 2014
Phase:
Study type: Observational

The purpose of this research is to investigate the efficacy of transplanting screened donor fecal material in treating patients with recurrent Clostridium difficile infection. Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema and their response will be evaluated by symptom questionnaire and stool testing for Clostridium difficile at 4 weeks after the treatment.

NCT ID: NCT02325791 Completed - Clinical trials for Respiratory Syncytial Virus Infections

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Start date: July 21, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age at the time of enrollment in their respective geographic location. In order to optimize the potential benefit in this vulnerable population, we conducted this study during the RSV season using dosing regimens that are expected to be effective.

NCT ID: NCT02321800 Completed - Clinical trials for Urinary Tract Infections

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

APEKS-cUTI
Start date: February 5, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine the efficacy and safety of intravenous cefiderocol (S-649266) in hospitalized adults with complicated urinary tract infections caused by Gram-negative pathogens.

NCT ID: NCT02319772 Completed - Clinical trials for Ebola Virus Infection

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430 administered via intramuscular (IM) injection in healthy subjects. In part 1, subjects will receive a single dose of BCX4430; in part 2 subjects will receive BCX4430 for 7 days.

NCT ID: NCT02309320 Completed - Clinical trials for Respiratory Syncytial Virus Infection

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of the study is to investigate the safety and tolerability of ALX-0171. The secondary objectives are to evaluate the clinical effect of ALX-0171 and to explore the pharmacodynamics (PD) and the systemic pharmacokinetics (PK) of ALX-0171.

NCT ID: NCT02307747 Completed - Infection Clinical Trials

Disruption of Circadian Rhythm and Healthcare-related Infection in Patients With Severe Trauma

Start date: February 17, 2015
Phase: N/A
Study type: Interventional

Circadian rhythms, which play crucial roles in physiology, are emerging as important regulators of specific immune functions. Hospitalization in intensive care unit leads to a deep impairment of circadian rhythm. Infection is a frequent event during ICU hospitalization. The investigators hypothesis is that in trauma patients the lack of circadian rhythm variations is associated with the occurrence of infection. The primary aim of the study is to assess the circadian variations of plasma Bmal1 in the occurrence of healthcare related infection during the 30 days after inclusion. The secondary aims are to assess the plasma expression of circadian genes (Clock, Cry1, Per3, and Rev-erba), the production of cytokines in plasma, and the concentration of cortisol, according to the occurrence of an infection.

NCT ID: NCT02306330 Completed - Clinical trials for Bacterial Infections

MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial

MALDITOF
Start date: December 2014
Phase: N/A
Study type: Interventional

MALDI-TOF MS is capable of directly identifying bacteria and fungi in positive blood cultures, which may be beneficial to patient management. Therefore, MALDI-TOF MS is an important new technology that is becoming routine in developed countries. It is currently unknown whether MALDITOF MS improves diagnostics, costs and patient outcomes in developing countries. This study will assess the clinical impact of a MALDITOF MS system (Maldi Biotyper, Bruker, Germany) in the resource constrained setting of Vietnam and at what cost.